Glucotrack Innovates Diabetes Management with Implantable Glucose Monitor
TL;DR
Glucotrack Inc.'s innovative CBGM system offers a competitive edge by providing more accurate, long-term glucose monitoring without the visibility or discomfort of wearables.
Glucotrack's CBGM system works by directly measuring blood glucose levels, eliminating inaccuracies and delays associated with interstitial fluid readings, and requires minimal maintenance for up to 3 years.
Glucotrack's CBGM system improves diabetes management by addressing patient concerns over accuracy and discomfort, fostering trust and enhancing quality of life for individuals with diabetes.
Glucotrack's fully implantable CBGM system marks a revolutionary step in diabetes care, offering a discreet, hassle-free solution with promising early clinical results.
Found this article helpful?
Share it with your network and spread the knowledge!
Glucotrack Inc. (NASDAQ: GCTK) is pioneering a new approach to diabetes management with its fully implantable continuous blood glucose monitoring (CBGM) system. The company's initiative stems from direct feedback from a Patient Advisory Board (PAB), comprising individuals living with type 1 diabetes, highlighting the distrust and challenges associated with current glucose monitoring technologies. This innovative system aims to overcome the limitations of traditional continuous glucose monitoring (CGM) systems, such as inaccuracy, compression lows, allergic reactions, and the emotional toll on patients.
The CBGM system by Glucotrack offers long-term functionality, requiring minimal maintenance and designed to last up to 3 years. Its fully implantable nature eliminates the need for adhesives, making it invisible to onlookers and free from the inconveniences of wearables. Moreover, it provides direct blood glucose measurements, improving the accuracy and reliability of real-time glucose data.
A first-in-human feasibility study conducted in Brazil showed promising results, with no serious adverse events reported and a 99% data capture rate. The system achieved an average Median Absolute Relative Difference (MARD) of 6.7%, outperforming most commercially available CGM systems. Glucotrack has now received ethical approval for a year-long clinical study in Australia, aiming to further evaluate the system's performance and safety.
With its upcoming presentations at the 2025 American Diabetes Association (ADA) Scientific Sessions, Glucotrack is set to showcase its CBGM system's potential to redefine diabetes care. The company's efforts underscore a commitment to leveraging technology to address the human aspects of diabetes management, offering hope for improved glycemic control and quality of life for patients worldwide.
Curated from NewMediaWire
